Výsledky vyhledávání - "Paula M Hale"

Liraglutide pharmacokinetics and exposure‐response in adolescents with obesity

Autor: Lucy D. Mastrandrea, Dan Hesse, Naveen Rathor, Kristin C. Carlsson Petri, Paula M Hale

Publikováno v: Pediatric Obesity

Background Obesity in adolescence presents a major public health challenge, often leading to obesity in adulthood with associated chronic disease. Objectives This study aimed to perform a population pharmacokinetic and exposure-response analysis of l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca64e4179022c1466d01bcf9434898a6
https://doi.org/10.1111/ijpo.12799

Zobrazit plný text záznamu

Effect of liraglutide treatment on body mass index and weight parameters in children and adolescents with type 2 diabetes: Post hoc analysis of the ellipse trial

Autor: Aaron S. Kelly, Megan O. Bensignor, T V S Divyalasya, Chethana Ramesh, Carolyn T. Bramante, Kyle Rudser, Paula M Hale, Eric M. Bomberg

Publikováno v: Pediatric Obesity

Summary Background Weight loss in children and adolescents with type 2 diabetes (T2D) is associated with improved glycaemic control. Objectives To assess the effects of liraglutide vs placebo on body mass index (BMI) and weight parameters in children

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7db66bd575adb95b0794e2d1f85c1dd
http://europepmc.org/articles/PMC8277686

Zobrazit plný text záznamu

Plný text ve formátu HTML

OR33-01 Liraglutide for Weight Management in Pubertal Adolescents with Obesity: A Randomized Controlled Trial

Autor: Margarita Barrientos-Pérez, Lucy D. Mastrandrea, Pernille Auerbach, Paula M Hale, Nandana Prabhu, Claude Marcus, Aaron S. Kelly, Inge Gies, Silva A. Arslanian

Publikováno v: Journal of the Endocrine Society

Background: Pediatric obesity is a chronic disease with rising prevalence and limited treatment options; first-line intervention is lifestyle therapy, which is typically unsuccessful.1 Liraglutide (3.0 mg) as an adjunct to lifestyle therapy has provi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e78f9e044c184152e18c2e3e5430f2b2
https://doi.org/10.1210/jendso/bvaa046.413

Zobrazit plný text záznamu

Liraglutide's Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Pediatric Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial

Autor: Paula M Hale, Silva A. Arslanian, Tadej Battelino, Lisbeth V. Jacobsen, D J Chatterjee, David J. Klein

Publikováno v: Diabetes Technology & Therapeutics. 16:679-687

The prevalence of type 2 diabetes (T2D) in youth is increasing. Treatment options beyond metformin and insulin are needed. The safety, tolerability, pharmacokinetics, and pharmacodynamics of liraglutide once daily in youth (10-17 years old) with T2D

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd69cb2e53ab9c26c37f975166738f94
https://doi.org/10.1089/dia.2013.0366

Zobrazit plný text záznamu

Liraglutide effects in a paediatric (7‐11 y) population with obesity: A randomized, double‐blind, placebo‐controlled, short‐term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics

Autor: Paula M Hale, Hanna K. Hedman, Kristin C. Carlsson Petri, Lucy D. Mastrandrea, Louise Witten, Robert A. Riesenberg

Publikováno v: Pediatric Obesity

Background Childhood obesity is a major public health concern with limited treatment options. Objective The aim of this study was to assess safety, tolerability, pharmacokinetics, and pharmacodynamics during short-term treatment with liraglutide in c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::938bfaccb7c261d26386b1085e6a7870
https://doi.org/10.1111/ijpo.12495

Zobrazit plný text záznamu

Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years

Autor: K Kapitzke, Thomas Danne, Torben Biester, Lisbeth V. Jacobsen, Kristin C. Carlsson Petri, Olga Kordonouri, Paula M Hale, Sanja Hald Jacobsen

Publikováno v: The Journal of pediatrics. 181

Objectives To investigate the safety, tolerability, and pharmacokinetics of liraglutide in adolescents with obesity. Study design This was a randomized, double-blind, placebo-controlled trial. Twenty-one subjects, aged 12-17 years and Tanner stage 2-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f04e233a2ac9e8a8ce435091747d477
https://pubmed.ncbi.nlm.nih.gov/27979579

Zobrazit plný text záznamu

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

Autor: Paula M Hale, Robert E. Ratner, C.T. Chang, Alan M. Garber, Bruce W. Bode, Robert R. Henry

Publikováno v: Diabetes, Obesity & Metabolism

Aims: Most treatments for type 2 diabetes fail over time, necessitating combination therapy. We investigated the safety, tolerability and efficacy of liraglutide monotherapy compared with glimepiride monotherapy over 2 years. Methods: Participants we

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::580dd30b7a938724af80a59fd7da3256
https://doi.org/10.1111/j.1463-1326.2010.01356.x

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání